Looking for a long Wave 3 to continue higher from here. There was some nice sideways action over the last few moths. Earnings came out on October 17th, sending price right through the old resistance, and initiating what I believe was leg 1 of another 5 wave move.
This is my first trade I post not only here, but also on my new blog (see footer) & chat here on TV.
I start this group education on TV because I see how many traders could be more successful, if they only had more knowledge, how to trade by combining high probability strategies.
My method is the combination of the Forks and Options.
But I also trade 100%...
Hi,
The title is bullish, but now we have a small congestion.
We must await until the break out for trade, if the price goes up than we can follow the trend. If the price goes down we can make profit with the retracement.
Every levels are drawn on the imagine.
As a reminder: Based on 17 analysts offering 12 month price targets for JNJ in the last 3 months:
The average price target is $ 147
The maximum price target is $ 165
The lowest price target is $ 110
The entry into this idea is currently at $ 144.33.
What say the technical analysis methods I use?
The risk management tool used here is the own-developed “Traffic...
As a reminder: Based on 17 analysts offering 12 month price targets for JNJ in the last 3 months:
The average price target is $ 147
The maximum price target is $ 165
The lowest price target is $ 110
The entry into this idea is currently at $ 144.33.
What say the technical analysis methods I use?
The risk management tool used here is the own-developed “Traffic...
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company. Includes more than 275 companies that sell its products in almost all countries of the world.
Newsflow:
Recently some good news for Johnson & Johnson!!! First of all, the Superior Court of California tossed the the record breaking...
Johnson & Johnson has been on an impressive intra-quarterly run with solid performance across major segments.
Strengths in the company's performance are to be driven by:
-Imbruvica and Darzalex should continue to perform well. Meaningful improvement from Stelara and Xarelto.
-New product launches like Tremfy (approved in the US late 2017 for plaque...
